For children aged 2 and up, India recommends the homemade Bharat Biotech Covid-19 vaccination


After reviewing its trial results for the two to 18 age range, India on Tuesday (Oct 12) authorized the emergency use of Bharat Biotech’s Covid-19 vaccination injection in children under the age of 12, making the vaccine producer the first in the country to receive such permission. The decision comes as India focuses on vaccinating youngsters against the coronavirus, having previously administered over 950 million doses to adults in its nearly 1.4 billion-strong population.
Covaxin, a vaccine developed by Bharat Biotech that combines an inactivated coronavirus with an immunity booster, is one of three injections used in India as part of an adult immunization campaign.
More than 110 million doses of Covaxin have been delivered, and the firm is working with the World Health Organization to obtain an emergency use listing, which is due later this month.To be sure, the two-dose injection is unlikely to be regarded as a simple vaccination throughout the world without the WHO’s approval.
“It is safe to wait until more people are covered for healthy children, given the minimal danger and low viral circulation at the present.”
Following a disastrous second wave of Covid-19, headed by the Delta variety, which knocked the country’s healthcare system to its knees, Bharat Biotech launched a study of Covaxin in children in June. The data for children aged two to eighteen years old “has been extensively examined by the Central Drugs Standard Control Organization and Subject Expert Committee, and (they) have offered favourable recommendations.”
The effectiveness and safety data for children have not been made public by Bharat Biotech. Only Zydus Cadila’s DNA-based vaccination was approved for emergency use in children aged 12 and up.


Please enter your comment!
Please enter your name here

Enable Google Transliteration.(To type in English, press Ctrl+g)